Post-Graduate Department in Medical School, University Nove de Julho (UNINOVE), São Paulo, São Paulo, Brazil.
Heart Institute, Clinical Hospital, Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Sao Paulo, Brazil.
Photobiomodul Photomed Laser Surg. 2022 Sep;40(9):622-631. doi: 10.1089/photob.2021.0177. Epub 2022 Sep 7.
Due to the high morbidity and mortality rates of this century, the COVID-19 pandemic has had a devastating impact on the health of the global population. The aim was to evaluate the disturbing impact of in-hospital stay length and the appeal of severe problems for supplemental oxygen for our patients with COVID-19 in moderate stage who were undergoing transvascular blood irradiation onto sublingual vessels. The demand for supplemental oxygen and the serum oxygen levels were measured, and the impact on the length of hospital stay was assessed. This randomized, prospective, clinical pilot study evaluated the diagnosis of COVID-19 patients admitted to the ventilatory care unit and undergoing treatment protocol usage of light-emitting diode (LED) irradiation by transvascular application onto the sublingual vessels daily. Patients were selected and enrolled into two groups: the Placebo group ( = 7) that received conventional treatment by the device off (LED-), and the photobiomodulation therapy (PBMT) group ( = 7) that also received the same therapy plus LED irradiation. There was a statistically significant clinical improvement, such as a reduction in serum creatinine, and oxygen usage per few days less in the PBMT group compared with the Placebo group. All patients in the PBMT group had normalized SatO, while a quarter of patients in the Placebo group required longer O supplementation until hospital discharge. The surveillance of clinical improvement in moderate stage indicated that the daily PBMT was able to diminish oxygen supplementation within a short time, besides reducing the hospital stay length in the PBMT group, particularly, when compared with the Placebo group. Clinical Trial Registration number: The study was reviewed by the Ethics Committee in UNINOVE research under number 42325020.6.0000.5511 and approved through number 5,090,119.
由于本世纪高发病率和死亡率，COVID-19 大流行对全球人口健康造成了破坏性影响。目的是评估经血管血辐照舌下血管对 COVID-19 中度患者住院时间和严重问题对补充氧气的吸引力的令人不安的影响。测量了补充氧气的需求和血清氧水平，并评估了对住院时间的影响。这项随机、前瞻性、临床试点研究评估了 COVID-19 患者的诊断，这些患者被收入通气护理病房并接受光疗（LED）经血管应用于舌下血管的每日治疗方案。患者被选择并分为两组：安慰剂组（n=7），接受设备关闭（LED-）的常规治疗，以及光生物调节治疗（PBMT）组（n=7），也接受相同的治疗加 LED 照射。与安慰剂组相比，PBMT 组的临床改善具有统计学意义，如血清肌酐降低，并且每几天的氧气使用量减少。PBMT 组所有患者的 SatO 均正常化，而安慰剂组中有四分之一的患者需要更长时间的氧气补充，直到出院。中度阶段的临床改善监测表明，每日 PBMT 能够在短时间内减少氧气补充，此外还缩短了 PBMT 组的住院时间，特别是与安慰剂组相比。临床试验注册号：该研究由 UNINOVE 研究伦理委员会审查，编号为 42325020.6.0000.5511，并通过编号 5,090,119 获得批准。
